On June 18th, Gelonhui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) plans to cancel its subsidiaries, Zhejiang Ruibo Life Science and Technology Co., Ltd. (referred to as "Ruibo Life Science") and Raybow Europe Incorporated ApS (referred to as "Ruibo Europe"), and authorize the management to handle the cancellation matters.
九洲药业(603456.SH)：拟注销子公司瑞博生命科学和瑞博欧洲
Zhejiang Jiuzhou Pharmaceutical (603456.SH): plans to cancel its subsidiaries Ruibo Life Sciences and Ruibo Europe.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.